UCB to present new positive data for Bimzelx at EULAR 22

23 May 2022

At the annual European Congress of Rheumatology (EULAR 2022), presentations will include new data from two Phase III studies of bimekizumab, BE MOBILE 1 and BE MOBILE 2.

Developed by Belgium’s UCB (Euronext: UCB), bimekizumab is an IL-17A and IL-17F-blocking antibody, approved in Europe and the UK for the treatment of moderate to severe plaque psoriasis, where it is marketed as Bimzelx.

In its approved indication, analysts have forecast sales for Bimzelx of around $1 billion at peak, well below the anticipated $8 billion forecast for psoriasis giant Skyrizi (risankizumab), an IL-23 targeting antibody sold by AbbVie (NYSE: ABBV).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK